Using of SGLt2 Inhibitors in Patients With Type 2 DM
Efficacy and Safety of Incorporating Sodium-glucose Cotransporter-2 Inhibitors to Regimens of Diabetes Patients Already Receiving Therapy
1 other identifier
observational
400
0 countries
N/A
Brief Summary
To detect the efficacy of SGLT2i in improving the metabolic parameters in patients with type 2 diabetes. \- To detect the side-effects of SGLT2i
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2024
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 17, 2024
CompletedFirst Posted
Study publicly available on registry
February 21, 2024
CompletedStudy Start
First participant enrolled
March 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
March 30, 2025
CompletedFebruary 21, 2024
February 1, 2024
1 year
January 17, 2024
February 17, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
Effect of adding SGLTi on BP
Compare the effect on blood pressure measurement ( SBP and DBP in mmHg) in SGLTi receivers and non SGLTi receivers
Six months
Effect of adding SGLTi on BMI
compare the effect on BMI ( weight in kg and height in m2) in SGLTi receivers and non SGLTi receivers.
Six months
Interventions
a class of prescription medicines that are FDA-approved for use with diet and exercise to lower blood sugar in adults with type 2 diabetes.
Eligibility Criteria
Adult diabetic type 2patients
You may qualify if:
- Adults (≥18 years)
- both genders ( male and female)
- type 2 diabetic patients
You may not qualify if:
- history of svere hypoglycemia
- patients with history of weight loss
- Patients with history of recurrent UTI
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (3)
Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, Pavkov ME, Ramachandaran A, Wild SH, James S, Herman WH, Zhang P, Bommer C, Kuo S, Boyko EJ, Magliano DJ. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022 Jan;183:109119. doi: 10.1016/j.diabres.2021.109119. Epub 2021 Dec 6.
PMID: 34879977BACKGROUNDLevine MJ. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials. Curr Diabetes Rev. 2017;13(4):405-423. doi: 10.2174/1573399812666160613113556.
PMID: 27296042BACKGROUNDVukadinovic D, Abdin A, Anker SD, Rosano GMC, Mahfoud F, Packer M, Butler J, Bohm M. Side effects and treatment initiation barriers of sodium-glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2022 Sep;24(9):1625-1632. doi: 10.1002/ejhf.2584. Epub 2022 Jul 8.
PMID: 35730422BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Resident doctor
Study Record Dates
First Submitted
January 17, 2024
First Posted
February 21, 2024
Study Start
March 1, 2024
Primary Completion
March 1, 2025
Study Completion
March 30, 2025
Last Updated
February 21, 2024
Record last verified: 2024-02